Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released its annual general meeting notice, which will take place virtually on May 9, 2023, at 4:00 p.m. Toronto time. Shareholders can view the management information circular on the company's website. Proxy solicitation is being handled by Laurel Hill Advisory Group, with a fee of $35,000 plus expenses. Shareholders are urged to vote before the 4:00 p.m. deadline on May 5, 2023. The board of directors recommends voting for all nominees and resolutions. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at enhancing anti-cancer immune responses, with ongoing clinical trials.
On March 28, 2023, Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that Dr. Matt Coffey, President and CEO, will participate in the 'Novel Mechanisms with Important Readouts' panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium from April 3-5, 2023. The panel is scheduled for April 3 at 11:00 a.m. ET. A live webcast and archived replay will be accessible to registered attendees. Oncolytics is advancing clinical trials for its immunotherapeutic agent, pelareorep, which enhances anti-cancer immune responses and targets various cancers, including metastatic breast and pancreatic cancer.
Oncolytics Biotech announced operational highlights and financial results for Q4 and full year 2022, emphasizing progress in its pancreatic and breast cancer programs. Notably, the phase 1/2 GOBLET trial showed a 69% objective response rate in advanced pancreatic cancer, leading to FDA Fast Track designation. The BRACELET-1 trial in metastatic breast cancer is on track for data readout in Q2 2023. As of December 31, 2022, the company reported $32.1 million in cash, providing a runway through anticipated milestones. The net loss for Q4 2022 was $8.6 million, and for the full year, it was $24.8 million, reflecting a decrease in losses compared to 2021.
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call and webcast to discuss its fourth quarter and full year 2022 financial results, scheduled for March 3, 2023, at 8:30 a.m. ET. The call will cover corporate updates and financial insights regarding the company’s lead immunotherapeutic agent, pelareorep, which is in trials for treating various cancers. The company is advancing towards registration studies in metastatic breast cancer and pancreatic cancer while evaluating pelareorep in combination with immune checkpoint inhibitors.
Oncolytics Biotech's partner Adlai Nortye presented interim results from a bridging clinical trial evaluating pelareorep-paclitaxel therapy for advanced HR+/HER2- breast cancer in Chinese patients. Out of 14 evaluable patients, 93% achieved disease control, with 86% showing tumor shrinkage. The median progression-free survival (PFS) was reported at 9.1 months. The combination therapy was well tolerated with no serious adverse events. Upcoming data from the ongoing BRACELET-1 trial are anticipated to further support pelareorep's development towards regulatory approval.
Oncolytics Biotech (NASDAQ: ONCY) announced FDA Fast Track designation for pelareorep combined with atezolizumab, gemcitabine, and nab-paclitaxel to treat advanced pancreatic ductal adenocarcinoma (PDAC). This designation follows a reported 69% objective response rate from their phase 1/2 GOBLET study, significantly higher than the historical average of ~25%. Fast Track status enables more frequent communication with the FDA, potentially leading to Accelerated Approval and Priority Review. Oncolytics is focused on pivotal trials for its core programs in breast and pancreatic cancer.
Oncolytics Biotech announced promising results from the phase 1/2 GOBLET study, demonstrating a 69% objective response rate (ORR) for first-line treatment of advanced pancreatic cancer, significantly outperforming the historical average of 25%. In total, 85% of patients showed a clinical benefit, with plans to advance to a pivotal study. The interim findings will be discussed in a key opinion leader webinar on November 14, 2022. The GOBLET study highlights the potential of pelareorep when combined with atezolizumab and chemotherapy, showing encouraging results for pancreatic cancer treatment.
Oncolytics Biotech reported significant interim data from its GOBLET trial, revealing a 70% objective response rate (ORR) for pancreatic cancer, nearly triple the historical average of 25%. The company holds $32.4 million in cash, projected to fund operations through 2023. They plan further studies for both pancreatic and breast cancer treatments, aiming for pivotal trials, with impactful results expected from their BRACELET-1 trial in early 2023. Despite a net loss of $4.4 million for Q3 2022, losses are down from $4.9 million during the same period last year.
Oncolytics Biotech reported interim results from the phase 1/2 GOBLET study for advanced pancreatic ductal adenocarcinoma, showing a 70% objective response rate (ORR), nearly three times higher than the average 25% from historical trials. The data indicates that pelareorep enhances the efficacy of PD-(L)1 inhibitors combined with standard chemotherapy. The company plans to engage regulators regarding expedited approval and will further discuss these findings in their upcoming earnings call.
Oncolytics Biotech announced a conference call on November 7, 2022, at 8:30 a.m. ET, to discuss its third-quarter financial results and corporate updates. The call will focus on the performance of pelareorep, an immunotherapeutic agent in development for various cancers, including its upcoming registration study in metastatic breast cancer. Interested parties can participate via a dial-in number or a webcast available on the company's Investor Relations page.
Further details and a replay option are provided in the press release.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
